Skip to main content

Medical materials

Publication
  • ERA
  • 4 June, 2026

Pegcetacoplan population pharmacokinetics and exposure-response analysis in adolescent and adult patients with C3G or primary IC-MPGN

David Kavanagh, Seung Hyeok Han, Larry A Greenbaum, Bradley P Dixon, Ali Keshavarz, Ryan L Crass, Brandon Smith, Xiaoying Yu, Priska Kaufmann

Publication
  • ERA
  • 4 June, 2026

Epidemiology of C3G and primary IC-MPGN: a systematic literature review and meta-analysis

Fernando Caravaca-Fontán, Carly Rich, Veruska Carboni, Jameel Nazir, Chris D Poole, Daniel P Gale

Publication
  • ERA
  • 4 June, 2026

Pegcetacoplan sustained clinical benefit in C3G and primary IC-MPGN through 1 year of therapy: Data from VALIANT/VALE

Fadi Fakhouri, Gema Ariceta, Matthew C Pickering, Moglie Le Quintrec, Marina Vivarelli, Carla M Nester, Bradley P Dixon, Virginia Taliadouros, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Christoph Licht

Publication
  • ERA
  • 4 June, 2026

Safety and low incidence of meningococcal infections with pegcetacoplan in C3G / primary IC-MPGN and PNH

Antonio Mastrangelo, Daniel P Gale, Daniel Zecher, Nabil Melhem, Sanya Norouzi, Bradley P Dixon, Sheena Patel, Liza Alkhori Franzén, Gashu Ayehu, Chauncey Clemons, Régis Peffault de Latour

Publication
  • ERA
  • 4 June, 2026

Decreasing rates of injection site reactions over time: Long-term outcomes across multiple indications support pegcetacoplan for C3G/primary IC-MPGN

Nabil Melhem, Antonio Mastrangelo, Daniel Zecher, Abdallah S Geara, Carla M Nester, Sheena Patel, Liza Alkhori Franzén, Andrew Carrel, Carlos de Castro, Daniel P Gale, Richard J. Kelly

Publication
  • ERA
  • 4 June, 2026

Pegcetacoplan treatment response in VALIANT/VALE: Impact of genetic and acquired complement dysregulation and disease type in C3G and primary IC-MPGN

Marina Norris, Nicole CAJ Van de Kar, Daniel P Gale, Sophie Chauvet, Fernando Caravaca-Fontán, Julia Weinmann-Menke, Carla M Nester, Lucía Quintana-Gallardo, Johan Szamosi, Kathryn Gordon, Anwesha Mukherjee, Fadi Fakhouri

Publication
  • ERA
  • 4 June, 2026

Real-world clinical profile, treatment patterns and outcomes associated with C3G and primary IC-MPGN: insights from the UK RaDaR registry

Lexy Sorrell, Carly Rich, Veruska Carboni, Jameel Nazir, David Pitcher, Edwin Wong, Katie Wong, Sherry Masoud, Daniel P Gale

Publication
  • ERA
  • 4 June, 2026

Pegcetacoplan treatment response in VALIANT/VALE: Impact of disease chronicity in C3G and primary IC-MPGN

Dean Wallace, Ana Ávila, Antonio Mastrangelo, François Provot, Daniel Zecher, Carla M Nester, Andrew S Bomback, Lucía Quintana-Gallardo, Johan Szamosi, Gashu Ayehu, Anwesha Mukherjee, Fadi Fakhouri

Sign up for alerts